1-Benzyl-1,2,3,4-Tetrahydroisoquinoline, an endogenous parkinsonism-inducing toxin, strongly potentiates mao-dependent dopamine oxidation and impairs dopamine release: Ex vivo and in vivo neurochemical studies

Neurotoxicity Research

Volumn 15, Issue 1, 2009, Pages 15-23

  Wa̧sik, Agnieszka ^a   Romańska, Irena ^a   Antkiewicz Michaluk, Lucyna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

1 Benzyl 1,2,3,4 tetrahydroisoquinoline (1BnTIQ); Dopamine and serotonin metabolism; Dopamine release; Microdialysis study; Rat brain structures

Indexed keywords

1 BENZYL 1,2,3,4 TETRAHYDROISOQUINOLINE; 3 O METHYLDOPAMINE; 3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; AMINE OXIDASE (FLAVIN CONTAINING); BRAIN MONOAMINE; DOPAMINE; ENDOTOXIN; HOMOVANILLIC ACID; NEUROTOXIN; SEROTONIN; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC TOXICITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; ELECTROCHEMICAL DETECTION; EX VIVO STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; LOCOMOTION; MALE; METABOLITE; MICRODIALYSIS; NEUROCHEMISTRY; NEUROTOXICITY; NONHUMAN; NUCLEUS ACCUMBENS; OXIDATION; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RAT; SEROTONIN METABOLISM; SUBSTANTIA NIGRA; WANDERING BEHAVIOR; WISTAR RAT;

ANALYSIS OF VARIANCE; ANIMALS; BASAL GANGLIA; BRAIN CHEMISTRY; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; MALE; MICRODIALYSIS; MOTOR ACTIVITY; MUSCLE RIGIDITY; NEUROTOXINS; RATS; RATS, WISTAR; TETRAHYDROISOQUINOLINES; TIME FACTORS;

PRIMATES; RATTUS; RATTUS NORVEGICUS; RODENTIA;

EID: 70349750316     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12640-009-9001-9     Document Type: Article

References (53)

1. Abe K, Taguchi K, Wasai T, Ren J, Utsunomiya I, Shinohara T, Miyatake T, Sano T (2001) Biochemical and pathological study of endogenous 1-benzyl-1,2,3,4-tetrahydroisoquinoline-induced parkinsonism in the mouse. Brain Res 907:134-138
2. Adamczyk A, Solecka J, Strosznajder JB (2005) Expression of α-synuclein in different brain parts of adult and aged rats. J Physiol Pharmacol 56:29-37
3. Adams JD Jr, Odunze IN (1991) Oxygen free radicals and Parkinson's disease. Free Radic Biol Med 10:161-169
4. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, Halliwell B (1997) Oxidative DNA damage in the parkinsonian brain: An apparent selective increase in 8-hydroxyquanine levels in substantia nigra. J Neurochem 69:1196-1203
5. Antkiewicz-Michaluk L, Krygowska-Wajs A, Michaluk J, Romańska I, Szczudlik A, Vetulani J (1999) Plasticity of extrapyramidal dopamine system in Parkinsons̀ disease: A postmortem study. Neurosci Res Commun 25:97-109
6. Antkiewicz-Michaluk L, Romańska I, Papla I, Michaluk J, Bakalarz M, Vetulani J, Krygowska-Wajs A, Szczudlik A (2000) Neurochemical changes induced by acute and chronic administration of 1,2,3,4-tetrahydroisoquinoline and salsolinol in dopaminergic structures of rat brain. Neuroscience 96:59-64
7. Antkiewicz-Michaluk L, Michaluk J, Mokrosz M, Romańska I, Lorenc-Koci E, Otha S, Vetulani J (2001) Different action on dopamine catabolic pathways of two endogenous 1,2,3,4-tetrahydroisoquinolines with similar antidopaminergic properties. J Neurochem 78:100-108
8. Antkiewicz-Michaluk L, Karolewicz B, Romańska I, Michaluk J, Bojarski A, Vetulani J (2003) 1-Methyl-1,2,3,4-tetrahydroisoquinoline protects against rotenone-induced mortality and biochemical changes in rat brain. Eur J Pharmacol 466:263-269
9. Antkiewicz-Michaluk L, Wardas J, Michaluk J, Romańska I, Bojarski A, Vetulani J (2004) Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone. Int J Neuropsychopharmacol 7:155-163
10. Burns RS, Lewitt PA, Ebert H, Pakkenberg H, Kopin IJ (1985) The clinical syndrome of striatal dopamine deficiency: Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-terahydropyridine (MPTP). N Engl J Med 312:1418-1421
11. Cannon JG, Webster GL (1958) Polyphosphoric acid in the Bischler-Napieralski reaction. J Am Pharm Assoc 47:353-358
12. Chan PH (1998) Oxygen radical mechanisms in cerebral ischemia and reperfusion, in ischemic stroke. In: Hsu CY (ed) Basic mechanisms to new drug development. Monogr clin neurosci, vol 16. Krager, Basel, pp 14-17
13. Chiba K, Trevor A, Castagnoli N Jr (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120:574-578
14. Colpaert FC (1987) Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. Neuropharmacology 26:1431-1440
15. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52:381-389
16. Dykens JA (1999) Free radicals and mitochondria dysfunction in exitotoxicity and neurodegenerative disease. In: Cell death and diseases of the nervous system. Humana Press, Totowa, NJ, pp 45-68
17. Egan MF, Karoum F, Wyatt RJ (1991) Effects of acute and chronic clozapine and haloperidol administration on 3-methoxytyramine accumulation in the rat prefrontal cortex, nucleus accumbens and striatum. Eur J Pharmacol 199:191-199
18. Fuller RW, Hemrick-Luecke SK, Perry KW (1988) Deprenyl atagonizes acute lethality of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J Pharmacol Exp Ther 247:531-535
19. Hao R, Ebadi M, Pfeiffer RF (1995a) Selegiline protects dopaminergic neurons in culture from toxic factor(s) present in the cerebrospinal fluid of patients with Parkinson's disease. Neurosci Lett 200:77-80
20. Hao R, Norgen RB Jr, Lau YS, Pfeiffer RF (1995b) Cerebrospinal fluid of Parkinson's disease patients inhibits the growth and function of dopaminergic neurons in culture. Neurology 45:138-142
21. Henry JP, Botton D, Sagne C, Isambert MF, Desnos C, Blanchard V, Raisman-Vozari R, Krejci E, Massoulie J, Gasnier B (1994) Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules. J Exp Biol 196:251-262
22. Inwang EE, Mosnaim AD, Sabelli HC (1973) Isolation and characterization of phenylethyleamine and phenylethanolamine from human brain. J Neurochem 20:1469-1473
23. Karoum F, Chrapusta SJ, Egan MF (1994) 3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: Reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in frontal cortex, nucleus accumbens and striatum by a simple two pool model. J Neurochem 63:972-978
24. Kostrzewa RM, Kostrzewa JP, Brus R (2000) Dopaminergic denervation enhances susceptibility to hydroxyl radicals in rat neostriatum. Amino Acids 19:183-199
25. Kotake Y, Tasaki Y, Makino Y, Otha S, Hirobe M (1995) 1-Benzyl-1,2,3,4-tetrahydroisoquinoline as a parkinsonism-inducing agent: A novel endogenous amine in mouse brain and parkinsonian CSF. J Neurochem 65:2633-2638
26. Kotake Y, Yoshida M, Ogawa M, Tasaki Y, Hirobe M, Ohta S (1996) Chronic administration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine in mouse brain and parkinsonian CSF. Neurosci Lett 217:69-71
27. Kotake Y, Ohta S, Kanazawa I, Sakurai M (2003) Neurotoxicity of an endogenous brain amine, 1-benzyl-1,2,3,4-tetrahydroisoquinoline, in organotypic slice co-culture of mesencephalon and striatum. Neurosience 117:63-70
28. Langston JW, Ballard P, Tetrud JW, Irvin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980
29. Lorenc-Koci E, Ossowska K, Wardas J, Wolfarth S (1995) Does reserpine induce parkinsonian rigidity? J Neural Transm Park Dis Dement Sect 9:211-223
30. Lorenc-Koci E, Antkiewicz-Michaluk L, Wardas J, Zapała M, Wierońska J (2004) Effect of 1,2,3,4-tetrahydroisoquinoline administration under conditions of CYP2D inhibition on dopamine metabolism, level of tyrosine hydroxylase protein and the binding of [3H]GBR 12, 935 to dopamine transporter in the rat nigrostriatal dopaminergic system. Brain Res 1009:67-81
31. Magyar K, Szende B, Lengyel J, Tarczali J, Szatmary I (1998) The neuroprotective and neuronal rescue effects of (-)-deprenyl. J Neural Transm Suppl 52:109-123
32. Miller J, Selhub J, Joseph J (1996) Oxidative damage caused by free radicals produced during catecholamine autooxidation: Protective effects of O-methylation and melatonin. Free Radic Biol Med 21:241-249
33. Mochizuki H, Goto K, Mori H, Mizuno Y (1996) Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci 137:120-123
34. Mogi A, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S, Ichinose H, Nagatsu T (2000) Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from Parkinsonian brain. J Neural Transm 107:335-341
35. Morikawa N, Naoi M, Maruyama W, Ohta S, Kotake Y, Kawai H, Niwa T, Dostert P, Mizuno Y (1998) Effects of various tetrahydroisoquinoline derivates on mitochondrial respiration and the electron transfer complexes. J Neural Transm 105:677-688
36. Moser A, Kompf D (1992) Presence of methyl-6, 7-dihydroxy-1,2,3,6-tetrahydroisoquinolines, derivatives of the neurotoxin isoquinoline, in parkinsonian lumbar CSF. Life Sci 50:1885-1891
37. Nagatsu T, Yoshida M (1988) An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxilase and biopterin in the nigrostriatal regions. Neurosci Lett 87:178-182
38. Naoi M, Matsuura S, Parvez H, Takahashi T, Hirata Y, Minami M, Nagatsu T (1989) Oxidation of N-methyl-1,2,3,4-tetrahydroisoquinoline into the N-methyl-isoquinolinium ion by monoamine oxidase. J Neurochem 52:653-655
39. Naoi M, Maruyama W, Akao Y, Yi H (2002) Dopamine-derived endogenous N-methyl-(R)-salsolinol: Its role in Parkinson's disease. Neurotoxicol Teratol 24:579-591
40. Nowak P, Szczerbak G, Biedka I, Drosik M, Kostrzewa RM, Brus R (2006) Efect of ketanserin and amphetamine on nigrostriatal neurotransmission and reactive oxygen species in parkinsonian rats. In vivo microdialysis study. J Physiol Pharmacol 57:583-597
41. Ohta S, Kohno M, Makino Y, Tachikawa O, Hirobe M (1987) Tetrahydroisoquinoline and 1-methyltetrahydroisoquinoline are present in the human brain: Relation to Parkinson's disease. Biomed Res 8:453-456
42. Okada T, Shimada S, Sato K, Kotake Y, Kawai H, Ohta S, Tohyama M, Nishimura T (1998) Tetrahydropapaveroline and its derivatives inhibit dopamine uptake through dopamine transporter expressed in HEK293 cells. Neurosci Res 30:87-90
43. Patsenka A, Antkiewicz-Michaluk L (2004) Inhibition of rodent brain monoamine oxidase and tyrosine hydroxylase by endogenous compounds 1,2,3,4-tetrahydroisoquinoline alkaloids. Pol J Pharmacol 56:727-734
44. Patsenka A, Michaluk J, Antkiewicz-Michaluk L (2004) 1,2,3,4-Tetrahydroisoquinoline alkaloids as endogenous inhibitors of brain monoamine oxidase, tyrosine hydroxylase and uptake of monoamines: in vitro study. In 13th international symposium on molecular and physiological aspects of regulatory processes of the organism, Krakow, Poland, Materials 2004, p 344
45. Schapira AH, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, Clark JB, Marsden CD (1990) Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 55:2142-2145
46. Schulz JB, Lindenau J, Seyfried J, Dichgans J (2000) Glutathione, oxidative stress and neurodegeneration. Eur J Biochem 267:4909-4911
47. Shavali S, Ebadi M (2003) 1-Benzyl-1,2,3,4-tetrahydroisoquinoline (1BnTIQ), an endogenous neurotoxin, induces dopaminergic cell death through apoptosis. Neuro Toxicol 24:417-424
48. Shavali S, Carlson EC, Swinscoe JC, Ebadi M (2004) 1-Benzyl-1,2,3,4-tetrahydroisoquinoline, a Parkinsonism-inducing endogenous toxin, increases α-synuclein expression and causes nuclear damage in human dopaminergic cells. J Neurosci Res 76:563-572
49. Spillantini MG, Goedert M (2000) The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci 920:16-27
50. Spina MB, Cohen G (1989) Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc Natl Acad Sci U S A 86:1389-1400
51. Stern G (1998) Neuroprotection by selegiline and other MAO inhibitors. J Neural Transm Suppl 52:99-107
52. Yamakawa T, Kotake Y, Fuijtani M, Shintani H, Makino Y, Otha S (1999) Regional distribution of parkinsonism-preventing endogenous tetrahydroisoquinoline derivatives and an endogenous parkinsonism-preventing substance-synthesizing enzyme in monkey brain. Neurosci Lett 276:68-70
53. Yoshida M, Niwa T, Nagatsu T (1990) Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: The behavioral and biochemical changes. Neurosci Lett 119:109-113